TRAIL/TNFSF10 Antibody - BSA Free

• Reactivity: Hu, Mu
• Applications: WB
• Clonality: Polyclonal
• Host: Rabbit
• Conjugate: Unconjugated
• Format: BSA Free
• Concentration: 1 mg/ml

TRAIL/TNFSF10 Antibody - BSA Free Summary

• Description: Novus Biologicals Rabbit TRAIL/TNFSF10 Antibody - BSA Free (NB500-220) is a polyclonal antibody validated for use in WB. Anti-TRAIL/TNFSF10 Antibody: Cited in 4 publications. All Novus Biologicals antibodies are covered by our 100% guarantee.
• Immunogen: residues [SNTLSSPNSKNE] of the N terminus of the TRAIL protein.
• Specificity: Reacts with residues [SNTLSSPNSKNE] of the N terminus of the TRAIL protein.
• Isotype: IgG
• Clonality: Polyclonal
• Host: Rabbit
• Gene: TNFSF10
• Purity: Immunogen affinity purified

Applications/Dilutions

• Dilutions:
  • Western Blot 1:100-1:2000
• Application Notes: Western blot- Use at 1:500 to 1:1,000 dilution. However, the investigator should determine the optimal dilution for a specific application such as immunohistochemistry
  
  The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• Theoretical MW: 36 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• Control:

  TRAIL/TNFSF10 Overexpression Lysate

Reactivity Notes

Human, Mouse reactivity reported in scientific literature (PMID: 1914164).

Packaging, Storage & Formulations

• Storage: Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
• Buffer: PBS
• Preservative: 0.02% Sodium Azide
• Concentration: 1 mg/ml
• Purity: Immunogen affinity purified

Alternate Names for TRAIL/TNFSF10 Antibody - BSA Free

• Apo-2 ligand
• APO2L
• Apo-2Ltumor necrosis factor (ligand) family, member 10
• APO2Ltumor necrosis factor apoptosis-inducing ligand splice variant delta
• CD253 antigen
• CD253
• Protein TRAIL
• TL2
• TNF-related apoptosis-inducing ligand
• TNFSF10
• TRAIL
• TRAILTNF-related apoptosis inducing ligand TRAIL
• tumor necrosis factor (ligand) superfamily, member 10
• tumor necrosis factor ligand superfamily member 10

Background

Apoptosis or programmed cell death is induced in cells by a group of death domain containing receptors. Binding of ligand to these receptors sends signals that activate members of the caspase family of proteases. The signals ultimately cause degradation of chromosomal DNA by activating DNase. TRAIL (TNF related apoptosis induced ligand) or Apo 2L initiates apoptosis of tumor cells by binding to either of its receptors, DR4 or DR5. These receptors consist of an extracellular TRAIL binding domain and a cytoplasmic "death domain". In addition, two decoy receptors for TRAIL have also been identified. These receptors, designated DcR1 and DcR2, lack the death domain. Binding of TRAIL to either of these receptors, therefore, does not transmit the death signal. Thus, these receptors represent a novel way of regulating cell sensitivity to a pro-apoptotic cytokine at the cell surface. TRAIL is expressed predominantly in spleen, lung, and prostate but also in many other tissues. TRAIL is a type II membrane protein from the TNF family. The human form of the protein is 281 amino acids in length, whereas the murine form is 291 amino acids. The two forms share 65% identity. Recombinant human TRAIL monomer has a molecular mass of approximately 21 kDa. Due to glycosylation, recombinant human TRAIL migrates as a 24 kDa protein in SDS PAGE.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for TRAIL/TNFSF10 Antibody (NB500-220)(5)

Publications using NB500-220

• Haagsma J, Kolendowski B, Buensuceso A et al. Gain-of-function p53 R175H blocks apoptosis in a precursor model of ovarian high-grade serous carcinoma Research Square 2023-03-24 (WB)
• Haagsma J, Kolendowski B, Buensuceso A et al. Gain-of-function p53(R175H) blocks apoptosis in a precursor model of ovarian high-grade serous carcinoma Scientific Reports 2023-07-14 [PMID: 37452087] (Western Blot, Mouse)
• Feng Y, Liu S, Zha R et al. Prostate cancer-associated urinary proteomes differ before and after prostatectomy Therapeutic advances in medical oncology 2022-10-27 [PMID: 36324734] (WB, Human)
• Feng Y, Liu S, Zha R, et al. Mechanical Loading-Driven Tumor Suppression Is Mediated by Lrp5-Dependent and Independent Mechanisms Cancers 2021-01-13 [PMID: 33450808] (WB, Mouse)
• Herzer K, Hofmann TG, Teufel A et al. IFN-{alpha}-Induced Apoptosis in Hepatocellular Carcinoma Involves Promyelocytic Leukemia Protein TRAIL Independently of p53. Cancer Res;69(3):855-62. 2009-02-01 [PMID: 19141642] (WB, Mouse)

Bioinformatics

• Gene Symbol: TNFSF10
• Entrez:
  • 8743(Human)